Helmbold P, Hegemann B, Holzhausen H J, Klapperstück T, Marsch W C
Department of Dermatology, Martin-Luther-Universität Halle-Wittenberg, Germany.
Arch Dermatol. 1998 Oct;134(10):1275-8. doi: 10.1001/archderm.134.10.1275.
The purpose of this study was to test the disease-controlling effect of low-dose oral etoposide monotherapy in adult-onset multisystem Langerhans cell histiocytosis. There are no previous reports of low-dose etoposide monotherapy for this condition.
A 27-year-old man with a 7-year history of multifocal chronic Langerhans cell histiocytosis presented with severe disabling ulcers in intertriginous areas. He had previously been treated with 2 different regimens of antitumoral chemotherapy; one had to be discontinued due to myelosuppression and the other had proved ineffective. We treated with oral etoposide monotherapy at 50 mg/d (22 mg/m2 per day) for 21 days. The treatment was repeated at 28-day intervals for a total of 6 cycles. A rapid initial response with subtotal diminution of the involved skin area was found. No adverse effects were observed. The clinical picture has remained stable during the 7 months following cessation of therapy.
Low-dose oral etoposide treatment is an adequate therapeutic measure for prolonged disease control in adult-type Langerhans cell histiocytosis.
本研究旨在测试低剂量口服依托泊苷单药治疗成人多系统朗格汉斯细胞组织细胞增多症的疾病控制效果。此前尚无关于低剂量依托泊苷单药治疗该病症的报道。
一名患有7年多灶性慢性朗格汉斯细胞组织细胞增多症的27岁男性，其腹股沟及腋窝等褶皱部位出现严重致残性溃疡。他此前曾接受过两种不同方案的抗肿瘤化疗；其中一种因骨髓抑制而停药，另一种则证明无效。我们采用口服依托泊苷单药治疗，剂量为50毫克/天（22毫克/平方米/天），持续21天。每28天重复一次治疗，共进行6个周期。发现初始反应迅速，受累皮肤面积几乎完全缩小。未观察到不良反应。在治疗停止后的7个月里，临床症状一直保持稳定。
低剂量口服依托泊苷治疗是成人型朗格汉斯细胞组织细胞增多症长期疾病控制的一种适当治疗措施。
